We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

TNXP Tonix Pharmaceuticals Holding Corporation

-0.0313 (-6.8%)
Last Updated: 13:04:23
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
Tonix Pharmaceuticals Holding Corporation TNXP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0313 -6.8% 0.4288 13:04:23
Open Price Low Price High Price Close Price Prev Close
0.4549 0.38 0.459 0.4601
more quote information »

Recent News

Date Time Source Heading
12/04/202307:10EDGAR2Form 8-K - Current report
12/04/202307:00GLOBETonix Pharmaceuticals Announces IND Clearance by the FDA for..
11/28/202307:00GLOBETonix Pharmaceuticals to Present at Two Upcoming Investor..
11/15/202307:05EDGAR2Form 8-K - Current report
11/15/202307:00GLOBETonix Pharmaceuticals Completes Clinical Stage of Phase 3..
11/13/202307:05EDGAR2Form 8-K - Current report
11/13/202307:00GLOBETonix Pharmaceuticals Announces Enrollment Initiated in Mass..
11/09/202316:27EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/09/202316:15GLOBETonix Pharmaceuticals Reports Third Quarter 2023 Financial..
11/02/202308:05EDGAR2Form 8-K - Current report
11/02/202308:00GLOBETonix Pharmaceuticals’ Vaccine Candidate, TNX-1800, Selected..
10/31/202317:06EDGAR2Form 8-K - Current report
10/31/202317:00GLOBETonix Pharmaceuticals Announces Topline Results from Phase 2..
10/30/202307:49EDGAR2Form 8-K - Current report
10/30/202307:00GLOBETonix Pharmaceuticals Announces New Data Involving TNX-1500..
10/26/202307:17EDGAR2Form 8-K - Current report
10/26/202307:00GLOBETonix Pharmaceuticals Completes Clinical Stage of Phase 2..
10/20/202317:07EDGAR2Form 8-K - Current report
10/20/202316:53EDGAR2Form PRE 14A - Other preliminary proxy statements
10/19/202307:05EDGAR2Form 8-K - Current report
10/18/202307:05EDGAR2Form 8-K - Current report
10/18/202307:00GLOBETonix Pharmaceuticals Announces Publication of Data in the..
10/16/202316:32EDGAR2Form 8-K - Current report
10/16/202307:05EDGAR2Form 8-K - Current report
10/16/202307:00GLOBETonix Pharmaceuticals Completes Clinical Stage of Phase 2..
10/12/202307:00GLOBETonix Pharmaceuticals to Present at the 2023 ThinkEquity..
10/11/202307:00GLOBETonix Pharmaceuticals Announces Oral Presentation at the..
10/09/202307:00GLOBETonix Pharmaceuticals Provides Overview of TNX-2900 Program..
10/04/202307:05EDGAR2Form 8-K - Current report
10/04/202307:00GLOBETonix Pharmaceuticals Announces Issuance of EU Patent..
9/29/202316:16EDGAR2Form 8-K - Current report
9/29/202316:15EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
9/28/202321:00GLOBETonix Pharmaceuticals Announces Pricing of $4.5 Million..
9/28/202316:03EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
9/28/202316:01GLOBETonix Pharmaceuticals Announces Proposed Public Offering
9/27/202308:35EDGAR2Form 8-K - Current report
9/27/202308:30GLOBETonix Pharmaceuticals Announces Department of Defense Grant..
9/25/202316:36EDGAR2Form 8-K - Current report
9/21/202307:05EDGAR2Form 8-K - Current report
9/21/202307:00GLOBETonix Pharmaceuticals Presents New Preclinical Data at..
9/18/202308:28EDGAR2Form 8-K - Current report
9/18/202307:00GLOBETonix Pharmaceuticals Announces Presentation of Non-Clinical..
9/15/202309:30GLOBENew to The Street Announces Episodes 510 and 511 Six..
9/14/202309:15EDGAR2Form 8-K - Current report
9/14/202307:00GLOBETonix Pharmaceuticals Announces Poster Presentation..
9/11/202308:31EDGAR2Form 8-K - Current report
9/06/202307:05EDGAR2Form 8-K - Current report
9/06/202307:00GLOBETonix Pharmaceuticals Announces Commitment to Supply..
9/05/202307:07EDGAR2Form 8-K - Current report
9/05/202307:00GLOBETonix Pharmaceuticals Announces Topline Results from Phase 2..

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |